These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Chemotherapy and rate of kill of tumor cells in a mouse plasmacytoma. Hiramoto RN; Ghanta VK Cancer Res; 1974 Jul; 34(7):1738-42. PubMed ID: 4833918 [No Abstract] [Full Text] [Related]
3. The use of rodent tumors in experimental cancer therapy. Conclusions and recommendations from an international workshop. Kallman RF; Brown JM; Denekamp J; Hill RP; Kummermehr J Cancer Res; 1985 Dec; 45(12 Pt 1):6541-5. PubMed ID: 4063999 [No Abstract] [Full Text] [Related]
4. Relationship of tumor regrowth to tumor cell survival, tumor cure rates and host survival in a solid tumor model following combined chemotherapy and radiotherapy. Hopkins HA; Looney WB; Carter WH; Reto DC; Campbell ED In Vivo; 1994; 8(1):97-105. PubMed ID: 8054518 [TBL] [Abstract][Full Text] [Related]
5. Clinical concepts derived from animal chemotherapy studies. Goldin A; Schabel FM Cancer Treat Rep; 1981; 65 Suppl 3():11-9. PubMed ID: 7049366 [TBL] [Abstract][Full Text] [Related]
6. Rationale for the use of alternating non-cross-resistant chemotherapy. Goldie JH; Coldman AJ; Gudauskas GA Cancer Treat Rep; 1982 Mar; 66(3):439-49. PubMed ID: 7060033 [No Abstract] [Full Text] [Related]
11. Timing is everything: preclinical evidence supporting simultaneous rather than sequential chemohormonal therapy for prostate cancer. Eigl BJ; Eggener SE; Baybik J; Ettinger S; Chi KN; Nelson C; Wang Z; Gleave ME Clin Cancer Res; 2005 Jul; 11(13):4905-11. PubMed ID: 16000589 [TBL] [Abstract][Full Text] [Related]
12. Assays for in vitro and in vivo synergy. Teicher BA Methods Mol Med; 2003; 85():297-321. PubMed ID: 12710216 [No Abstract] [Full Text] [Related]
13. [Possibilities and limits of neoplasm drug therapy]. Senn HJ Schweiz Rundsch Med Prax; 1972 Jul; 61(27):877-83. PubMed ID: 4680951 [No Abstract] [Full Text] [Related]
14. [Therapeutic ratio in combined radio-chemotherapy--radiobiological considerations]. Sasaki T Gan No Rinsho; 1983 Oct; 29(13):1584-93. PubMed ID: 6668668 [TBL] [Abstract][Full Text] [Related]
15. Lovastatin potentiates antitumor activity and attenuates cardiotoxicity of doxorubicin in three tumor models in mice. Feleszko W; Mlynarczuk I; Balkowiec-Iskra EZ; Czajka A; Switaj T; Stoklosa T; Giermasz A; Jakóbisiak M Clin Cancer Res; 2000 May; 6(5):2044-52. PubMed ID: 10815931 [TBL] [Abstract][Full Text] [Related]
16. [Use of xenografts for the evaluation of tumor chemotherapy. Application to adjuvant chemotherapy]. Duplan JF Bull Cancer; 1984; 71(4):292-6. PubMed ID: 6498344 [TBL] [Abstract][Full Text] [Related]
17. Modelling in tumour biology part 1: modelling concepts and structures. Rew DA Eur J Surg Oncol; 2000 Feb; 26(1):87-94. PubMed ID: 10718187 [TBL] [Abstract][Full Text] [Related]
18. Primary bone lymphoma: treatment results and prognostic factors with long-term follow-up of 82 patients. Beal K; Allen L; Yahalom J Cancer; 2006 Jun; 106(12):2652-6. PubMed ID: 16700039 [TBL] [Abstract][Full Text] [Related]
19. Orthotopic metastatic (MetaMouse) models for discovery and development of novel chemotherapy. Hoffman RM Methods Mol Med; 2005; 111():297-322. PubMed ID: 15911987 [TBL] [Abstract][Full Text] [Related]
20. Efficacy with a replication-selective adenovirus plus cisplatin-based chemotherapy: dependence on sequencing but not p53 functional status or route of administration. Heise C; Lemmon M; Kirn D Clin Cancer Res; 2000 Dec; 6(12):4908-14. PubMed ID: 11156251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]